首页 > 最新文献

Chinese Medical Journal最新文献

英文 中文
In-hospital outcomes of anemic patients with acute coronary syndrome receiving ticagrelor versus clopidogrel: Results of the Chinese Cardiovascular Care Improvement (CCC)-Acute Coronary Syndrome Project. 接受替卡格雷与氯吡格雷治疗的急性冠脉综合征贫血患者的院内预后:中国心血管治疗改进项目(CCC)--急性冠脉综合征项目的结果。
IF 7.5 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-10-20 Epub Date: 2024-09-05 DOI: 10.1097/CM9.0000000000003279
Zhiqiang Zhang, Yasong Wang, Jun Wang, Xiaofan Cao, Miaohan Qiu, Xiaoxiang Tian, Yaling Han, Xiaozeng Wang
{"title":"In-hospital outcomes of anemic patients with acute coronary syndrome receiving ticagrelor versus clopidogrel: Results of the Chinese Cardiovascular Care Improvement (CCC)-Acute Coronary Syndrome Project.","authors":"Zhiqiang Zhang, Yasong Wang, Jun Wang, Xiaofan Cao, Miaohan Qiu, Xiaoxiang Tian, Yaling Han, Xiaozeng Wang","doi":"10.1097/CM9.0000000000003279","DOIUrl":"10.1097/CM9.0000000000003279","url":null,"abstract":"","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":"2489-2491"},"PeriodicalIF":7.5,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11479518/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142139429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Population pharmacokinetics of Ainuovirine and exposure-response analysis in human immunodeficiency virus-infected individuals. 人类免疫缺陷病毒感染者体内阿依诺韦林的群体药代动力学和暴露-反应分析。
IF 7.5 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-10-20 Epub Date: 2024-06-27 DOI: 10.1097/CM9.0000000000002917
Xiaoxu Han, Jin Sun, Yihang Zhang, Taiyi Jiang, Qingshan Zheng, Haiyan Peng, Yao Wang, Wei Xia, Tong Zhang, Lijun Sun, Xinming Yun, Hong Qin, Hao Wu, Bin Su

Background: Ainuovirine (ANV) is a new generation of non-nucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus (HIV) type 1 infection. This study aimed to evaluate the population pharmacokinetic (PopPK) profile and exposure-response relationship of ANV among people living with HIV.

Methods: Plasma concentration-time data from phase 1 and phase 3 clinical trials of ANV were pooled for developing the PopPK model. Exposure estimates obtained from the final model were used in exposure-response analysis for virologic responses and safety responses.

Results: ANV exhibited a nonlinear pharmacokinetic profile, which was best described by a two-compartment model with first-order elimination. There were no significant covariates correlated to the pharmacokinetic parameters of ANV. The PopPK parameter estimate (relative standard error [%]) for clearance adjusted for bioavailability (CL/F) was 6.46 (15.00) L/h, and the clearance of ANV increased after multiple doses. The exposure-response model revealed no significant correlation between the virologic response (HIV-RNA <50 copies/mL) at 48 weeks and the exposure, but the incidence of adverse events increased with the increasing exposure ( P value of steady-state trough concentration and area under the steady-state curve were 0.0177 and 0.0141, respectively).

Conclusions: Our PopPK model supported ANV 150 mg once daily as the recommended dose for people living with HIV, requiring no dose adjustment for the studied factors. Optimization of ANV dose may be warranted in clinical practice due to an increasing trend in adverse reactions with increasing exposure.

Trial registration: Chinese Clinical Trial Registry https://www.chictr.org.cn (Nos. ChiCTR1800018022 and ChiCTR1800019041).

背景:Ainuovirine(ANV)是治疗人类免疫缺陷病毒(HIV)1型感染的新一代非核苷类逆转录酶抑制剂。本研究旨在评估ANV在HIV感染者中的群体药代动力学(PopPK)特征和暴露-反应关系:方法:汇集 ANV 1 期和 3 期临床试验的血浆浓度-时间数据,建立 PopPK 模型。从最终模型中获得的暴露估计值用于病毒学应答和安全性应答的暴露-应答分析:结果:ANV表现出非线性药代动力学特征,用一阶消除的两室模型对其进行了最佳描述。没有明显的协变量与ANV的药代动力学参数相关。CL/F的PopPK参数估计值(相对标准误差[%])为6.46 (15.00) L/h,多次给药后ANV的清除率增加。暴露-反应模型显示病毒学反应(HIV-RNA 结论)之间无显著相关性:我们的 PopPK 模型支持将 ANV 150 毫克每日一次作为 HIV 感染者的推荐剂量,无需根据研究因素调整剂量。由于不良反应有随着暴露量增加而增加的趋势,临床实践中可能需要优化ANV的剂量:中国临床试验注册中心 https://www.chictr.org.cn(编号:ChiCTR1800018022 和 ChiCTR1800019041)。
{"title":"Population pharmacokinetics of Ainuovirine and exposure-response analysis in human immunodeficiency virus-infected individuals.","authors":"Xiaoxu Han, Jin Sun, Yihang Zhang, Taiyi Jiang, Qingshan Zheng, Haiyan Peng, Yao Wang, Wei Xia, Tong Zhang, Lijun Sun, Xinming Yun, Hong Qin, Hao Wu, Bin Su","doi":"10.1097/CM9.0000000000002917","DOIUrl":"10.1097/CM9.0000000000002917","url":null,"abstract":"<p><strong>Background: </strong>Ainuovirine (ANV) is a new generation of non-nucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus (HIV) type 1 infection. This study aimed to evaluate the population pharmacokinetic (PopPK) profile and exposure-response relationship of ANV among people living with HIV.</p><p><strong>Methods: </strong>Plasma concentration-time data from phase 1 and phase 3 clinical trials of ANV were pooled for developing the PopPK model. Exposure estimates obtained from the final model were used in exposure-response analysis for virologic responses and safety responses.</p><p><strong>Results: </strong>ANV exhibited a nonlinear pharmacokinetic profile, which was best described by a two-compartment model with first-order elimination. There were no significant covariates correlated to the pharmacokinetic parameters of ANV. The PopPK parameter estimate (relative standard error [%]) for clearance adjusted for bioavailability (CL/F) was 6.46 (15.00) L/h, and the clearance of ANV increased after multiple doses. The exposure-response model revealed no significant correlation between the virologic response (HIV-RNA <50 copies/mL) at 48 weeks and the exposure, but the incidence of adverse events increased with the increasing exposure ( P value of steady-state trough concentration and area under the steady-state curve were 0.0177 and 0.0141, respectively).</p><p><strong>Conclusions: </strong>Our PopPK model supported ANV 150 mg once daily as the recommended dose for people living with HIV, requiring no dose adjustment for the studied factors. Optimization of ANV dose may be warranted in clinical practice due to an increasing trend in adverse reactions with increasing exposure.</p><p><strong>Trial registration: </strong>Chinese Clinical Trial Registry https://www.chictr.org.cn (Nos. ChiCTR1800018022 and ChiCTR1800019041).</p>","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":"2473-2482"},"PeriodicalIF":7.5,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11479413/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141455677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cerebellar involvement in Parkinson's disease: Pathophysiology and neuroimaging. 帕金森病的小脑受累:病理生理学和神经影像学
IF 7.5 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-10-20 Epub Date: 2024-09-03 DOI: 10.1097/CM9.0000000000003248
Tao Qiu, Meichen Liu, Xinhui Qiu, Tianbai Li, Weidong Le

Abstract: Parkinson's disease (PD) is a neurodegenerative disease characterized by various motor and non-motor symptoms. The complexity of its symptoms suggests that PD is a heterogeneous neurological disorder. Its pathological changes are not limited to the substantia nigra-striatal system, but gradually extending to other regions including the cerebellum. The cerebellum is connected to a wide range of central nervous system regions that form essential neural circuits affected by PD. In addition, altered dopaminergic activity and α-synuclein pathology are found in the cerebellum, further suggesting its role in the PD progression. Furthermore, an increasing evidence obtained from imaging studies has demonstrated that cerebellar structure, functional connectivity, and neural metabolism are altered in PD when compared to healthy controls, as well as among different PD subtypes. This review provides a comprehensive summary of the cerebellar pathophysiology and results from neuroimaging studies related to both motor and non-motor symptoms of PD, highlighting the potential significance of cerebellar assessment in PD diagnosis, differential diagnosis, and disease monitoring.

摘要:帕金森病(PD)是一种以各种运动和非运动症状为特征的神经退行性疾病。其症状的复杂性表明帕金森病是一种异质性神经系统疾病。其病理变化并不局限于黑质-纹状体系统,而是逐渐扩展到包括小脑在内的其他区域。小脑与中枢神经系统的多个区域相连,形成受帕金森病影响的重要神经回路。此外,小脑还存在多巴胺能活动改变和α-突触核蛋白病变,这进一步表明了小脑在帕金森病进展过程中的作用。此外,越来越多的影像学研究证据表明,与健康对照组相比,以及在不同的帕金森病亚型中,帕金森病患者的小脑结构、功能连接和神经代谢均发生了改变。本综述全面总结了小脑病理生理学以及与帕金森病运动和非运动症状相关的神经影像学研究结果,强调了小脑评估在帕金森病诊断、鉴别诊断和疾病监测中的潜在意义。
{"title":"Cerebellar involvement in Parkinson's disease: Pathophysiology and neuroimaging.","authors":"Tao Qiu, Meichen Liu, Xinhui Qiu, Tianbai Li, Weidong Le","doi":"10.1097/CM9.0000000000003248","DOIUrl":"10.1097/CM9.0000000000003248","url":null,"abstract":"<p><strong>Abstract: </strong>Parkinson's disease (PD) is a neurodegenerative disease characterized by various motor and non-motor symptoms. The complexity of its symptoms suggests that PD is a heterogeneous neurological disorder. Its pathological changes are not limited to the substantia nigra-striatal system, but gradually extending to other regions including the cerebellum. The cerebellum is connected to a wide range of central nervous system regions that form essential neural circuits affected by PD. In addition, altered dopaminergic activity and α-synuclein pathology are found in the cerebellum, further suggesting its role in the PD progression. Furthermore, an increasing evidence obtained from imaging studies has demonstrated that cerebellar structure, functional connectivity, and neural metabolism are altered in PD when compared to healthy controls, as well as among different PD subtypes. This review provides a comprehensive summary of the cerebellar pathophysiology and results from neuroimaging studies related to both motor and non-motor symptoms of PD, highlighting the potential significance of cerebellar assessment in PD diagnosis, differential diagnosis, and disease monitoring.</p>","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":"2395-2403"},"PeriodicalIF":7.5,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11479504/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142124986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Curbing alcohol-associated liver disease by increasing alcohol excise taxes. 通过提高酒精消费税遏制酒精相关肝病。
IF 7.5 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-10-20 Epub Date: 2024-08-23 DOI: 10.1097/CM9.0000000000003201
Feiyu Zhang, Peng Xiao, Yali Liu, Tao Liu, Yanhang Gao
{"title":"Curbing alcohol-associated liver disease by increasing alcohol excise taxes.","authors":"Feiyu Zhang, Peng Xiao, Yali Liu, Tao Liu, Yanhang Gao","doi":"10.1097/CM9.0000000000003201","DOIUrl":"10.1097/CM9.0000000000003201","url":null,"abstract":"","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":"2412-2414"},"PeriodicalIF":7.5,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11479448/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142035421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnostic accuracy of a simplified tool for irritable bowel syndrome with predominant constipation in Chinese patients: A multicenter, prospective, observational study. 中国患者以便秘为主的肠易激综合征简化工具的诊断准确性:一项多中心、前瞻性、观察性研究。
IF 7.5 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-10-20 Epub Date: 2024-08-26 DOI: 10.1097/CM9.0000000000003246
Mei Luo, Jinsong Liu, Zhe Zhang, Jin Tao, Youxiang Chen, Xiuling Li, Xiaoping Zou, Jing Sun, Jie Jin, Huahong Wang, Lishou Xiong
{"title":"Diagnostic accuracy of a simplified tool for irritable bowel syndrome with predominant constipation in Chinese patients: A multicenter, prospective, observational study.","authors":"Mei Luo, Jinsong Liu, Zhe Zhang, Jin Tao, Youxiang Chen, Xiuling Li, Xiaoping Zou, Jing Sun, Jie Jin, Huahong Wang, Lishou Xiong","doi":"10.1097/CM9.0000000000003246","DOIUrl":"10.1097/CM9.0000000000003246","url":null,"abstract":"","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":"2509-2511"},"PeriodicalIF":7.5,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11479474/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142055076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Applying a trauma custom bridge system to reconstruct critical-sized femoral and tibial defects: Finite element analysis, osseointegration, and clinical outcomes. 应用创伤定制桥系统重建临界大小的股骨和胫骨缺损:有限元分析、骨结合和临床效果。
IF 7.5 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-10-20 Epub Date: 2024-09-12 DOI: 10.1097/CM9.0000000000003235
Bingchuan Liu, Xingcai Li, Zhengguang Wang, Zhuo Chen, Fang Zhou, Zhongwei Yang, Guojin Hou, Min Liu, Kai Song, Caimei Wang, Yun Tian
{"title":"Applying a trauma custom bridge system to reconstruct critical-sized femoral and tibial defects: Finite element analysis, osseointegration, and clinical outcomes.","authors":"Bingchuan Liu, Xingcai Li, Zhengguang Wang, Zhuo Chen, Fang Zhou, Zhongwei Yang, Guojin Hou, Min Liu, Kai Song, Caimei Wang, Yun Tian","doi":"10.1097/CM9.0000000000003235","DOIUrl":"10.1097/CM9.0000000000003235","url":null,"abstract":"","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":"2515-2517"},"PeriodicalIF":7.5,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11479456/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142281172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Does the microaneurysm have to be distinguished from a similar-sized dot hemorrhage? 是否必须将微动脉瘤与类似大小的点状出血区分开来?
IF 7.5 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-10-20 Epub Date: 2024-06-14 DOI: 10.1097/CM9.0000000000003166
Yueqing He, Xi Huang, Sheng Gao, Meixia Zhang, Junjun Zhang
{"title":"Does the microaneurysm have to be distinguished from a similar-sized dot hemorrhage?","authors":"Yueqing He, Xi Huang, Sheng Gao, Meixia Zhang, Junjun Zhang","doi":"10.1097/CM9.0000000000003166","DOIUrl":"10.1097/CM9.0000000000003166","url":null,"abstract":"","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":"2504-2506"},"PeriodicalIF":7.5,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11479462/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141327312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Incidence, mortality, and disability-adjusted life years of female breast cancer in China, 2022. 2022 年中国女性乳腺癌的发病率、死亡率和残疾调整生命年。
IF 7.5 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-10-20 Epub Date: 2024-09-05 DOI: 10.1097/CM9.0000000000003278
Kexin Sun, Bailin Zhang, Shaoyuan Lei, Rongshou Zheng, Xin Liang, Li Li, Xiaolong Feng, Siwei Zhang, Hongmei Zeng, Yifei Yao, Peiqing Ma, Shaoming Wang, Ru Chen, Bingfeng Han, Wenqiang Wei, Jie He

Background: Breast cancer is ranked among the most prevalent malignancies in the Chinese female population. However, comprehensive reports detailing the latest epidemiological data and attributable disease burden have not been extensively documented.

Methods: In 2018, high-quality cancer surveillance data were recorded in 700 population-based cancer registries in China. We extracted data on female breast cancers (International Classification of Diseases, Tenth Revision [ICD-10]: C50) and estimated the incidence and mortality in 2022 according to the baseline data and corresponding trends from 2010 to 2018. Pathological types were classified according to the ICD for Oncology, 3rd Edition codes. Disability-adjusted life years (DALYs) were calculated as the sum of the years of life lost (YLLs) and years lived with disability (YLDs).

Results: In 2022, approximately 357,200 new female breast cancer cases and 75,000 deaths occurred in China, accounting for 15.59% and 7.94% of total new cancer cases and deaths, respectively. The age-standardized incidence rate (ASIR) was 33.04 per 100,000. When analyzed by pathological type, the ASIRs for papillary neoplasms, invasive breast carcinoma, rare and salivary gland-type tumors, and other types were 1.13, 29.79, 0.24, and 1.88 per 100,000, respectively. The age-standardized mortality rate (ASMR) was 6.10 per 100,000. A total of 2,628,000 DALYs were found to be attributable to female breast cancer in China, comprising 2,278,300 YLLs and 349,700 YLDs. The ASIR, ASMR, and age-standardized rate (ASR) for DALYs in urban areas were consistently higher than those in rural areas. We observed a four-fold increase in the ASIR and ASR for DALYs and an eight-fold increase in the ASMR among females over 55 years compared with those aged under 55 years.

Conclusion: These data provide invaluable insights into the latest epidemiology of female breast cancer in China and highlight the urgency for disease prevention and control strategy formulation.

背景乳腺癌是中国女性人口中发病率最高的恶性肿瘤之一。然而,详细记录最新流行病学数据和可归因疾病负担的综合报告并不广泛:2018 年,中国 700 个基于人群的癌症登记处记录了高质量的癌症监测数据。我们提取了女性乳腺癌(国际疾病分类第十版 [ICD-10]:C50)的数据,并根据基线数据和 2010 年至 2018 年的相应趋势估算了 2022 年的发病率和死亡率。病理类型根据《国际肿瘤疾病分类》第三版代码进行分类。残疾调整生命年(DALYs)的计算方法是损失生命年(YLLs)和残疾生活年(YLDs)之和:2022年,中国女性乳腺癌新发病例约为35.72万例,死亡病例约为7.5万例,分别占癌症新发病例和死亡病例总数的15.59%和7.94%。年龄标准化发病率(ASIR)为33.04/10万。按病理类型分析,乳头状瘤、浸润性乳腺癌、罕见和唾液腺型肿瘤以及其他类型的年龄标准化发病率分别为每 10 万人 1.13 例、29.79 例、0.24 例和 1.88 例。年龄标准化死亡率(ASMR)为每 10 万人 6.10 例。中国女性乳腺癌导致的残疾调整寿命年数为262.8万年,包括227.83万年残疾调整寿命年数和34.97万年残疾调整寿命年数。城市地区的DALYs ASIR、ASMR和年龄标准化率(ASR)一直高于农村地区。我们观察到,与 55 岁以下女性相比,55 岁以上女性的 DALYs ASIR 和 ASR 增加了四倍,ASMR 增加了八倍:这些数据为了解中国女性乳腺癌的最新流行病学情况提供了宝贵的信息,并凸显了制定疾病预防和控制策略的紧迫性。
{"title":"Incidence, mortality, and disability-adjusted life years of female breast cancer in China, 2022.","authors":"Kexin Sun, Bailin Zhang, Shaoyuan Lei, Rongshou Zheng, Xin Liang, Li Li, Xiaolong Feng, Siwei Zhang, Hongmei Zeng, Yifei Yao, Peiqing Ma, Shaoming Wang, Ru Chen, Bingfeng Han, Wenqiang Wei, Jie He","doi":"10.1097/CM9.0000000000003278","DOIUrl":"10.1097/CM9.0000000000003278","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer is ranked among the most prevalent malignancies in the Chinese female population. However, comprehensive reports detailing the latest epidemiological data and attributable disease burden have not been extensively documented.</p><p><strong>Methods: </strong>In 2018, high-quality cancer surveillance data were recorded in 700 population-based cancer registries in China. We extracted data on female breast cancers (International Classification of Diseases, Tenth Revision [ICD-10]: C50) and estimated the incidence and mortality in 2022 according to the baseline data and corresponding trends from 2010 to 2018. Pathological types were classified according to the ICD for Oncology, 3rd Edition codes. Disability-adjusted life years (DALYs) were calculated as the sum of the years of life lost (YLLs) and years lived with disability (YLDs).</p><p><strong>Results: </strong>In 2022, approximately 357,200 new female breast cancer cases and 75,000 deaths occurred in China, accounting for 15.59% and 7.94% of total new cancer cases and deaths, respectively. The age-standardized incidence rate (ASIR) was 33.04 per 100,000. When analyzed by pathological type, the ASIRs for papillary neoplasms, invasive breast carcinoma, rare and salivary gland-type tumors, and other types were 1.13, 29.79, 0.24, and 1.88 per 100,000, respectively. The age-standardized mortality rate (ASMR) was 6.10 per 100,000. A total of 2,628,000 DALYs were found to be attributable to female breast cancer in China, comprising 2,278,300 YLLs and 349,700 YLDs. The ASIR, ASMR, and age-standardized rate (ASR) for DALYs in urban areas were consistently higher than those in rural areas. We observed a four-fold increase in the ASIR and ASR for DALYs and an eight-fold increase in the ASMR among females over 55 years compared with those aged under 55 years.</p><p><strong>Conclusion: </strong>These data provide invaluable insights into the latest epidemiology of female breast cancer in China and highlight the urgency for disease prevention and control strategy formulation.</p>","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":"2429-2436"},"PeriodicalIF":7.5,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11479498/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142139428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mortality, morbidity, and care practices for 1750 very low birth weight infants, 2016-2021. 2016-2021年,对1750名出生体重极轻婴儿的死亡率、发病率和护理方法进行的回顾性队列研究。
IF 7.5 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-10-20 Epub Date: 2024-02-26 DOI: 10.1097/CM9.0000000000002923
Yang He, Meng Zhang, Jun Tang, Wanxiu Liu, Yong Hu, Jing Shi, Hua Wang, Tao Xiong, Li Zhang, Junjie Ying, Dezhi Mu

Background: Very low birth weight (VLBW) infants are the key populations in neonatology, wherein morbidity and mortality remain major challenges. The study aimed to analyze the clinical characteristics of VLBW infants.

Methods: A retrospective cohort study was conducted in West China Second Hospital between January 2016 and December 2021. Neonates with a birth weight of <1500 g were included. Mortality, care practices, and major morbidities were analyzed, and compared with those of previous 7 years (2009-2015).

Results: Of the total 1750 VLBW, 1386 were infants born with birth weight between 1000-1499 g and 364 infants were born with weight below 1000 g; 42.9% (751/1750) required delivery room resuscitation; 53.9% (943/1750) received non-invasive ventilation only; 38.2% (669/1750) received invasive ventilation; 1517 VLBW infants received complete treatment. Among them, 60.1% (912/1517) of neonates had neonatal respiratory distress syndrome (NRDS), 28.7% (436/1517) had bronchopulmonary dysplasia (BPD), 22.0% (334/1517) had apnea, 11.1% (169/1517) had culture-confirmed sepsis, 8.4% (128/1517) had pulmonary hemorrhage, 7.6% (116/1517) had severe intraventricular hemorrhage (IVH)/periventricular leukomalacia (PVL), 5.7% (87/1517) had necrotizing enterocolitis (NEC), and 2.0% (31/1517) had severe retinopathy of prematurity. The total and in-hospital mortality rates were 9.7% (169/1750) and 3.0% (45/1517), respectively. The top three diagnoses of death among those who had received complete treatment were sepsis, NRDS, and NEC. In 2009-2015, 1146 VLBW were enrolled and 895 infants received complete treatment. The proportions of apnea, IVH, and IVH stage ≥3/PVL, were higher in 2009-2015 compared with those in 2016-2021, while the proportions of NRDS and BPD were characterized by significant increases in 2016-2021. The total and in-hospital mortality rates were 16.7% (191/1146) and 5.6% (50/895) respectively in 2009-2015.

Conclusion: Among VLBW infants born in 2016-2021, the total and in-hospital mortality rates were lower than those of neonates born in 2009-2015. Incidences of NRDS and BPD increased in 2016-2021, which affected the survival rates and long-term prognosis of VLBW.

背景:极低出生体重儿(VLBW)是新生儿科的重点人群,其发病率和死亡率仍是主要挑战:方法:开展一项回顾性队列研究,旨在分析 2016 年 1 月至 2021 年 12 月期间我院极低出生体重儿的临床特征。新生儿出生体重为 0.5 千克:在1750例VLBW中,1386例出生体重在1000-1499克之间,364例低于1000克,42.9%(751/1750)需要产房复苏,53.9%(943/1750)仅接受无创通气,38.2%(669/1750)接受有创通气;1517例VLBW婴儿接受了完全治疗。其中,60.1%(912/1517)的新生儿患有新生儿呼吸窘迫综合征(NRDS),28.7%(436/1517)的新生儿患有支气管肺发育不良(BPD),22.0%(334/1517)的新生儿患有呼吸暂停,11.1%(169/1517)的新生儿患有经培养证实的败血症,8.4%(128/1517)有肺出血,7.6%(116/1517)有严重脑室内出血(IVH)/脑室周围白质异常(PVL),5.7%(87/1517)有坏死性小肠结肠炎(NEC),2.0%(31/1517)有严重早产儿视网膜病变。总死亡率和院内死亡率分别为 9.7%(169/1750)和 3.0%(45/1517)。在接受完全治疗的患者中,死亡诊断的前三位分别是败血症、NRDS 和 NEC。2009-2015 年,共有 1146 名低龄早产儿入组,其中 895 名婴儿接受了完全治疗。与 2016-2021 年相比,2009-2015 年呼吸暂停、IVH 和 IVH 分期≥3/PVL 的发生率较高,而 2016-2021 年 NRDS 和 BPD 的发生率显著增加。2009-2015年的总死亡率和院内死亡率分别为16.7%(191/1146)和5.6%(50/895):结论:在2016-2021年出生的低体重儿中,总死亡率和院内死亡率均低于2009-2015年出生的新生儿。2016-2021年NRDS和BPD的发生率增加,影响了VLBW的存活率和长期预后。
{"title":"Mortality, morbidity, and care practices for 1750 very low birth weight infants, 2016-2021.","authors":"Yang He, Meng Zhang, Jun Tang, Wanxiu Liu, Yong Hu, Jing Shi, Hua Wang, Tao Xiong, Li Zhang, Junjie Ying, Dezhi Mu","doi":"10.1097/CM9.0000000000002923","DOIUrl":"10.1097/CM9.0000000000002923","url":null,"abstract":"<p><strong>Background: </strong>Very low birth weight (VLBW) infants are the key populations in neonatology, wherein morbidity and mortality remain major challenges. The study aimed to analyze the clinical characteristics of VLBW infants.</p><p><strong>Methods: </strong>A retrospective cohort study was conducted in West China Second Hospital between January 2016 and December 2021. Neonates with a birth weight of <1500 g were included. Mortality, care practices, and major morbidities were analyzed, and compared with those of previous 7 years (2009-2015).</p><p><strong>Results: </strong>Of the total 1750 VLBW, 1386 were infants born with birth weight between 1000-1499 g and 364 infants were born with weight below 1000 g; 42.9% (751/1750) required delivery room resuscitation; 53.9% (943/1750) received non-invasive ventilation only; 38.2% (669/1750) received invasive ventilation; 1517 VLBW infants received complete treatment. Among them, 60.1% (912/1517) of neonates had neonatal respiratory distress syndrome (NRDS), 28.7% (436/1517) had bronchopulmonary dysplasia (BPD), 22.0% (334/1517) had apnea, 11.1% (169/1517) had culture-confirmed sepsis, 8.4% (128/1517) had pulmonary hemorrhage, 7.6% (116/1517) had severe intraventricular hemorrhage (IVH)/periventricular leukomalacia (PVL), 5.7% (87/1517) had necrotizing enterocolitis (NEC), and 2.0% (31/1517) had severe retinopathy of prematurity. The total and in-hospital mortality rates were 9.7% (169/1750) and 3.0% (45/1517), respectively. The top three diagnoses of death among those who had received complete treatment were sepsis, NRDS, and NEC. In 2009-2015, 1146 VLBW were enrolled and 895 infants received complete treatment. The proportions of apnea, IVH, and IVH stage ≥3/PVL, were higher in 2009-2015 compared with those in 2016-2021, while the proportions of NRDS and BPD were characterized by significant increases in 2016-2021. The total and in-hospital mortality rates were 16.7% (191/1146) and 5.6% (50/895) respectively in 2009-2015.</p><p><strong>Conclusion: </strong>Among VLBW infants born in 2016-2021, the total and in-hospital mortality rates were lower than those of neonates born in 2009-2015. Incidences of NRDS and BPD increased in 2016-2021, which affected the survival rates and long-term prognosis of VLBW.</p>","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":"2452-2460"},"PeriodicalIF":7.5,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11479399/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139971079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Invasive electrical nerve stimulation for post-stroke motor rehabilitation. 用于中风后运动康复的侵入性神经电刺激。
IF 7.5 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-10-20 Epub Date: 2024-09-10 DOI: 10.1097/CM9.0000000000003286
Xianze Li, Tao Xue, Zixiao Li, Jianguo Zhang
{"title":"Invasive electrical nerve stimulation for post-stroke motor rehabilitation.","authors":"Xianze Li, Tao Xue, Zixiao Li, Jianguo Zhang","doi":"10.1097/CM9.0000000000003286","DOIUrl":"10.1097/CM9.0000000000003286","url":null,"abstract":"","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":"2495-2497"},"PeriodicalIF":7.5,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11479480/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142281184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Chinese Medical Journal
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1